Rituximab is linked to lower risks for renal complications than cyclophosphamide in adult patients with immunoglobulin A vasculitis.

Although relapse rates were similar across all treatment categories, patients with GPA treated with rituximab monotherapy had a lower relapse risk relative to those on rituximab + cyclophosphamide ...

Targeted therapies have been moved forward in the treatment of both pemphigus and pemphigoid diseases, a factor behind an urgency for rapid diagnosis.

Please provide your email address to receive an email when new articles are posted on . Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but ...

No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...

Rituximab (Rituxan) did not show noninferiority compared with ocrelizumab (Ocrevus) in relapsing-remitting multiple sclerosis (MS), according to registry data. The annualized relapse rate (ARR) was ...

Please provide your email address to receive an email when new articles are posted on . Results of a study showed that antirituximab antibodies are common among patients with pemphigus who have been ...

The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab ...

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

In 2006, we published the results of the European Organisation for Research and Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission induction and maintenance ...